Credit Suisse Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $185

Credit Suisse maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $190 to $185.

Benzinga · 12/24/2019 12:44

Credit Suisse maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $190 to $185.